Literature DB >> 31723010

Cas12a/Guide RNA-Based Platform for Rapid and Accurate Identification of Major Mycobacterium Species.

Guohui Xiao1,2, Xing He1, Su Zhang1, Yaya Liu1, Zhihang Liang3, Houming Liu1, Juanjuan Zhang1, Min Ou1, Shuhao Cai1, Wenjie Lai1, Tianyu Zhang2, Lili Ren4, Guoliang Zhang5,3.   

Abstract

Mycobacterium tuberculosis infection and nontuberculous mycobacteria (NTM) infections exhibit similar clinical symptoms; however, the therapies for these two types of infections are different. Therefore, the rapid and accurate identification of M. tuberculosis and NTM species is very important for the control of tuberculosis and NTM infections. In the present study, a Cas12a/guide RNA (gRNA)-based platform was developed to identify M. tuberculosis and most NTM species. By designing species-specific gRNA probes targeting the rpoB sequence, a Cas12a/gRNA-based platform successfully identified M. tuberculosis and six major NTM species (Mycobacterium abscessus, Mycobacterium intracellulare, Mycobacterium avium, Mycobacterium kansasii, Mycobacterium gordonae, and Mycobacterium fortuitum) without cross-reactivity. In a blind assessment, a total of 72 out of 73 clinical Mycobacterium isolates were correctly identified, which is consistent with previous rpoB sequencing results. These results suggest that the Cas12a/gRNA-based platform is a promising tool for the rapid, accurate, and cost-effective identification of both M. tuberculosis and NTM species.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  CRISPR/Cas12a; Mycobacterium tuberculosis; biosensing; fluorescence; gRNA probe; identification; nontuberculous mycobacteria

Mesh:

Substances:

Year:  2020        PMID: 31723010      PMCID: PMC6989083          DOI: 10.1128/JCM.01368-19

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  40 in total

Review 1.  Diagnosis of nontuberculous mycobacterial infections.

Authors:  Barbara A Brown-Elliott; David E Griffith; Richard J Wallace
Journal:  Clin Lab Med       Date:  2002-12       Impact factor: 1.935

2.  PCR restriction fragment length polymorphism analysis (PRA)-algorithm targeting 644 bp Heat Shock Protein 65 (hsp65) gene for differentiation of Mycobacterium spp.

Authors:  Hong Kim; Sun-Hyun Kim; Tae-Sun Shim; Mi-na Kim; Gill-Han Bai; Young-Gil Park; Sueng-Hyun Lee; Chang-Yong Cha; Yoon-Hoh Kook; Bum-Joon Kim
Journal:  J Microbiol Methods       Date:  2005-08       Impact factor: 2.363

Review 3.  The prevalence of non-tuberculous mycobacterial infections in mainland China: Systematic review and meta-analysis.

Authors:  Xia Yu; Pengnian Liu; Guan Liu; Liping Zhao; Yanjie Hu; Guomei Wei; Jingjing Luo; Hairong Huang
Journal:  J Infect       Date:  2016-10-04       Impact factor: 6.072

4.  Novel DNA chip based on a modified DigiTag2 assay for high-throughput species identification and genotyping of Mycobacterium tuberculosis complex isolates.

Authors:  Prapaporn Srilohasin; Angkana Chaiprasert; Katsushi Tokunaga; Nishida Nao; Therdsak Prammananan
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

5.  Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics.

Authors:  Wenjuan Nie; Hongfei Duan; Hairong Huang; Yu Lu; Dapeng Bi; Naihui Chu
Journal:  Int J Infect Dis       Date:  2014-06-13       Impact factor: 3.623

6.  Increasing Prevalence Rate of Nontuberculous Mycobacteria Infections in Five States, 2008-2013.

Authors:  Maura J Donohue; Larry Wymer
Journal:  Ann Am Thorac Soc       Date:  2016-12

7.  Rapid detection and differentiation of mycobacterial species using a multiplex PCR system.

Authors:  Andrea Santos Lima; Rafael Silva Duarte; Lílian Maria Lapa Montenegro; Haiana Charifker Schindler
Journal:  Rev Soc Bras Med Trop       Date:  2013 Jul-Aug       Impact factor: 1.581

8.  [Evaluation of combination of BACTEC mycobacteria growth indicator tube 960 system and Ogawa media for mycobacterial culture].

Authors:  Eunsin Bae; Ji Hoon Im; Sung Won Kim; Nam Surp Yoon; Heungsup Sung; Mi Na Kim; Tae Sun Shim
Journal:  Korean J Lab Med       Date:  2008-08

9.  CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA.

Authors:  Shi-Yuan Li; Qiu-Xiang Cheng; Jia-Kun Liu; Xiao-Qun Nie; Guo-Ping Zhao; Jin Wang
Journal:  Cell Res       Date:  2018-03-12       Impact factor: 25.617

Review 10.  Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease: Clinicians' Perspectives.

Authors:  Yon Ju Ryu; Won-Jung Koh; Charles L Daley
Journal:  Tuberc Respir Dis (Seoul)       Date:  2016-03-31
View more
  4 in total

1.  CRISPR-Cas fluorescent cleavage assay coupled with recombinase polymerase amplification for sensitive and specific detection of Enterocytozoon hepatopenaei.

Authors:  Suthasinee Kanitchinda; Jiraporn Srisala; Rungkarn Suebsing; Anuphap Prachumwat; Thawatchai Chaijarasphong
Journal:  Biotechnol Rep (Amst)       Date:  2020-06-06

2.  A CRISPR/Cas12a-assisted rapid detection platform by biosensing the apxIVA of Actinobacillus pleuropneumoniae.

Authors:  Tian Luan; Lu Wang; Jiyu Zhao; Hui Luan; Yueling Zhang; Chunlai Wang; Paul R Langford; Siguo Liu; Wanjiang Zhang; Gang Li
Journal:  Front Microbiol       Date:  2022-09-09       Impact factor: 6.064

Review 3.  CRISPR-Based Programmable Nucleic Acid-Binding Protein Technology Can Specifically Detect Fatal Tropical Disease-Causing Pathogens.

Authors:  Md Rashidur Rahman; Toma Rani Majumder; Md Aminul Islam Apu; Alok K Paul; Afrina Afrose; Biplab Kumar Dash
Journal:  J Trop Med       Date:  2022-07-18

4.  A Recombinase Polymerase Amplification-Coupled Cas12a Mutant-Based Module for Efficient Detection of Streptomycin-Resistant Mutations in Mycobacterium tuberculosis.

Authors:  Peng Liu; Xinjie Wang; Juan Liang; Qian Dong; Jinping Zhang; Dongxin Liu; Shuai Wang; Jing Bi; Wenqi Liu; Zhaoqin Wang; Liang Chen; Lei Liu; Xingxu Huang; Guoliang Zhang
Journal:  Front Microbiol       Date:  2022-01-06       Impact factor: 5.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.